Figure 1 | Scientific Reports

Figure 1

From: Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration

Figure 1

Plasma levels of VEGF-A, VWF antigen, and ADAMTS13 activity in patients with untreated exudative AMD and controls. (A) Plasma levels of VEGF-A in patients with AMD were significantly lower than those in controls (**p < 0.01). The minimum detectable dose (MDD) of VEGF-A defined by the manufacturer was 9 pg/ml. (B) Plasma levels of VWF antigen (:Ag) in patients with age-related macular degeneration (AMD) were significantly higher than those in controls (***p < 0.001). (C) Plasma ADAMTS13 activity (:AC) levels in patients with AMD were almost the same as those in controls.

Back to article page